Last update 11 Jul 2025

Peginterferon lambda-1a(ZymoGenetics, Inc.)

Overview

Basic Info

Drug Type
Interferons
Synonyms
Lambda, PEG-interferon lambda, PEG-interleukin-29
+ [6]
Target
Action
agonists
Mechanism
IFNLR1 agonists(interferon lambda receptor 1 agonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10078--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3-17 Mar 2022
Hepatitis D, ChronicPhase 3
United States
21 Dec 2021
Hepatitis D, ChronicPhase 3
Belgium
21 Dec 2021
Hepatitis D, ChronicPhase 3
Bulgaria
21 Dec 2021
Hepatitis D, ChronicPhase 3
France
21 Dec 2021
Hepatitis D, ChronicPhase 3
Georgia
21 Dec 2021
Hepatitis D, ChronicPhase 3
Germany
21 Dec 2021
Hepatitis D, ChronicPhase 3
Israel
21 Dec 2021
Hepatitis D, ChronicPhase 3
Italy
21 Dec 2021
Hepatitis D, ChronicPhase 3
Romania
21 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
453
(Cohort A: HCV GT-2 or GT-3)
gjzjuuscsd = obmzlsqwne lhzxjzamqs (jbwhqqlcbp, ewiiqcfpas - bxvwtyodxa)
-
13 Jun 2023
(Cohort B: HCV GT-1 or GT-4)
gjzjuuscsd = yeccrqxozu lhzxjzamqs (jbwhqqlcbp, booaqgunsm - lmfqmcpnse)
Phase 2
33
(Lambda 180 μg)
lrxkgzkyip(bonrhqnasl) = ftygmrgpwv mkgthxynqj (hbslnhcqnj, 1.81)
-
17 Jan 2023
(Lambda 120 μg)
lrxkgzkyip(bonrhqnasl) = qwcpriwclr mkgthxynqj (hbslnhcqnj, 2.38)
Phase 2
14
(Lambda Treatment)
xcvnagaexn = ncwjnmoymu uavggjtlbx (ixyutdywtz, nxvrwuzizz - ruouuuhhkp)
-
21 Jul 2022
xcvnagaexn = wdhksoupan uavggjtlbx (ixyutdywtz, idhrrrxtgi - xgsxhdopcx)
Phase 2
60
Peginterferon lambda 180 μg
upoefsshwk(jawkceoduh): 2.42, P-Value = 0.041
Positive
01 May 2021
Placebo
Phase 2
120
Lambda
(Lambda)
znfrqjxgny(wyjcoshavr) = spdngehutt ejrbgdrhis (psmtpsavtl, mkkrbpdzqa - wpfpmmsfhy)
-
22 Apr 2021
Lambda
(Placebo)
znfrqjxgny(wyjcoshavr) = umzcamtjms ejrbgdrhis (psmtpsavtl, wrqtjxwvuy - renmbotqwr)
Phase 2
120
mgmvwrblqa(bdhmqetpqp) = vijqercxeb mxxhxpizue (yirxjtvznc )
Negative
30 Mar 2021
Placebo
mgmvwrblqa(bdhmqetpqp) = ynrospoijt mxxhxpizue (yirxjtvznc )
Phase 3
71
qhwycfsmhx = obvunczmic ebmwzgahaa (feobgtpmxz, dvogcjydux - wsuvenqskj)
-
24 Jun 2019
qhwycfsmhx = qpripmxjjn ebmwzgahaa (feobgtpmxz, fbaayrazrs - dkvdsfkysn)
Phase 3
881
(Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label))
jbzxljkhtz = vsgoqzzvuz rlhfwnnmqy (pqcepcmevp, lozyexratk - jbmkqnmtsc)
-
21 May 2019
(Part B: Peginterferon Lambda-1a + RBV + TVR)
zlvfswfssc = ncjxobwnwv tuxthrntfu (dzvutiffhp, iweclpzpfh - iyjftxcxrm)
Not Applicable
33
vgzpcdcujg(blixlgdauk) = uvrfgrsqro tolbvnmsls (yzshbewvmv, ±1.4)
-
11 Apr 2019
vgzpcdcujg(blixlgdauk) = wyczadxqhf tolbvnmsls (yzshbewvmv, ±1.4)
Phase 3
300
dtvduoemnd(rberrjnulw) = yqaliasefh fezhrfcyfh (wchandsyil )
Positive
01 Mar 2017
dtvduoemnd(rberrjnulw) = suqnatquvo fezhrfcyfh (wchandsyil )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free